WHO WE ARE

---

Expanding into the United States represents a significant opportunity for Aenitis Tech, which has established a strong presence in France. As we embark on this strategic expansion, several key factors will shape our approach and ensure our success in this dynamic and competitive market.

Market Potential

The United States is the largest medical device market in the world, valued at over $180 billion and projected to grow annually. This dramatic growth is fueled by an aging population, technological advancements, and an increasing demand for innovative healthcare solutions. Our company is well-positioned to capitalize on these trends, particularly given our expertise in developing cutting-edge medical devices designed to improve patient outcomes.

Conclusion

In conclusion, expanding into the United States from France is an exciting and strategic move for Aenitis Tech. By focusing on regulatory compliance, building strategic partnerships, understanding cultural differences, and investing in targeted marketing efforts, we can establish a strong foothold in one of the world’s largest healthcare markets. As we embark on this journey, we remain committed to our mission of improving patient outcomes through innovative medical devices and look forward to contributing to the advancement of healthcare in the United States.

At Aenitis, we understand the critical importance of  precision and efficiency when it comes to cell handling in research,  clinical and manufacturing environment.

We have developed a  sole-in-class platform based on acoustic levitation in flow that enables  gentle, non-invasive manipulation of cells at the millifluidic scale,  allowing tens of milliliters per minute to be handled. This patented  technology uses acoustic waves to levitate cells without physical  contact, minimizing mechanical stress and preserving cell viability and  functionality. This high-precision approach enhances yields, reduces  costs, and improves cell quality, advancing the fields of cell and gene  therapy and biomanufacturing.

As the industry faces a growing demand for scalable and  cost-effective solutions, Aenitis is set to address these challenges  with its groundbreaking technology. A spin-off from the CNRS (the  National Center for Scientific Research) and ESPCI (ParisTech research  engineer’s school) Paris, co-founded by Emmanuel Vincent, Mauricio Hoyos  and Jean-Luc Aider, the company has developed a platform based on  acoustic levitation in flow that enables gentle, non-invasive  manipulation of cells at the millifluidic scale, allowing tens of  milliliters per minute to be handled.

Our team of experts share a deep passion for advancing the quality of  cell processing through innovative biotechnology solutions. Meet the  people driving our success.